FRMD4A and non-small cell lung carcinoma: PE‐Erl consisted of NEK7, SLCO3A1, RELB, FRMD4A, HSD17B2, CDK6, PALM, IL1RN, SMYD1, BAG2, GNG3 and SULT1E1 and was used to predict chemotherapy response in NSCLC patients.